Retinal gene therapy advancements may rewrite the book on treatments for age-related macular degeneration and diabetic eye diseases.

Stained tissue was viewed with a confocal microscope (TCS SP8; Leica, DE). Using 40× objective lens, either the photoreceptor or ganglion cell layer was fully scanned at a digital step of 0.3 μm.

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened its label as a treatment for diabetic macular edema (DME), which is the ...

In addition to rod photoreceptor loss ... Identifying mechanisms of cell–cell interactions initiated by rod-specific mutations and affecting other retinal cells is important for understanding ...

The FDA has approved Genentech’s Susvimo (ranibizumab) to treat patients with diabetic macular edema (DME), a leading cause of vision loss in adults with diabetes. Diabetic macular edema affects about ...

Please provide your email address to receive an email when new articles are posted on . The approval was supported by 1-year results from the phase 3 Pagoda study. Susvimo is also approved for wet ...

The US Food and Drug Administration (FDA) has approved ranibizumab injection) 100 mg/mL (Susvimo; Genentech) for the treatment of diabetic macular edema (DME). The company noted that Susvimo is the ...

A HEARTBROKEN mum says she "nearly died" hearing her little girl's diagnosis - after the tot's face kept swelling following ... This revealed she had a giant cell tumour - a rare and aggressive ...

Dysfunction of the retinal pigment epithelium (RPE) is a unifying salient feature of the pathology and a primary end-point damage leading to complications such as geographic atrophy (GA), which ...

The Fraunhofer Institute for Microstructure of Materials and Systems IMWS has developed a new method known as laser swelling that ... of nearsightedness: retinal detachment, cataracts or macular ...

The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant ...